2 weeks Ago By ABMN Staff
Quest Partners LLC boosted its stake in shares of Kymera Therapeutics, Inc. ( NASDAQ:KYMR – Free Report ) by 1,402.0% during the 2nd quarter, according to its most recent 13F filing with the SEC.
The firm owned 5,212 shares of the company’s stock after buying an additional 4,865 shares during the period. Quest Partners LLC’s holdings in Kymera Therapeutics were worth $156,000 as of its most recent filing with the SEC. Other institutional investors and hedge funds also recently made changes to their positions in the company.
Price T Rowe Associates Inc. MD lifted its position in Kymera Therapeutics by 18.7% in the 1st quarter.
Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after acquiring an additional 996,300 shares in the last quarter. Vanguard Group Inc.
lifted its holdings in shares of Kymera Therapeutics by 19.2% in the first quarter. Vanguard Group Inc.
now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after purchasing an additional 769,486 shares in the last quarter. Norges Bank acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth about $12,834,000. Artal Group S.
A. grew its holdings in shares of Kymera Therapeutics by 19.6% during the first quarter.
Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after buying an additional 496,400 shares in the last quarter.
Finally, Goldman Sachs Group Inc. raised its position in Kymera Therapeutics by 229.6% in the 4th quarter.
Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after buying an additional 469,947 shares during the last quarter. Kymera Therapeutics Stock Up 5.
2 % KYMR stock opened at $48.48 on Tuesday. The company’s 50-day moving average price is $44.
57 and its two-hundred day moving average price is $38.89. The firm has a market cap of $2.
97 billion, a P/E ratio of -19.31 and a beta of 2.22.
Kymera Therapeutics, Inc. has a 12 month low of $9.60 and a 12 month high of $50.
19. Insider Activity at Kymera Therapeutics In related news, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $38.
21, for a total transaction of $17,345,811.60. Following the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.
66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link . In related news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th.
The stock was sold at an average price of $38.21, for a total value of $17,345,811.60.
Following the sale, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total transaction of $1,060,272.
45. Following the completion of the transaction, the insider now owns 95,470 shares in the company, valued at approximately $4,373,480.70.
The disclosure for this sale can be found here . Insiders sold a total of 482,105 shares of company stock valued at $18,651,584 in the last quarter. Insiders own 15.
82% of the company’s stock. Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on KYMR shares. B.
Riley raised their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th.
Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research note on Monday, August 26th.
HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research report on Monday, June 17th. Finally, Wells Fargo & Company upped their target price on Kymera Therapeutics from $30.
00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock.
Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.67.
Check Out Our Latest Stock Analysis on Kymera Therapeutics Kymera Therapeutics Company Profile ( Free Report ) Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. Further Reading Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. ( NASDAQ:KYMR – Free Report ). Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
